Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the completion of the transaction, the chief executive officer now owns 686,062 shares of the company’s stock, valued at $36,176,049.26. This trade represents a 4.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Andrew Cheng also recently made the following trade(s):

• On Monday, January 27th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.90, for a total transaction of $1,647,000.00.
• On Tuesday, December 10th, Andrew Cheng sold 7,855 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $241,855.45.
• On Monday, December 2nd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.09, for a total transaction of $802,250.00.

Akero Therapeutics Stock Performance

Shares of AKRO traded down $1.20 during trading hours on Tuesday, hitting $49.95. The company had a trading volume of 1,594,471 shares, compared to its average volume of 1,884,203. The firm has a market cap of $3.49 billion, a price-to-earnings ratio of -13.32 and a beta of -0.11. The business has a fifty day moving average of $33.42 and a 200-day moving average of $30.24. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Equities analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HC Wainwright increased their target price on shares of Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Canaccord Genuity Group upped their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Citigroup upped their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Finally, Morgan Stanley upped their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds have recently bought and sold shares of AKRO. Mirae Asset Global Investments Co. Ltd. grew its stake in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Akero Therapeutics by 5.0% during the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock worth $584,000 after buying an additional 1,000 shares in the last quarter. Swiss National Bank grew its stake in Akero Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 95,600 shares of the company’s stock worth $2,660,000 after buying an additional 1,100 shares in the last quarter. Rhumbline Advisers grew its stake in Akero Therapeutics by 1.3% during the fourth quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock worth $2,940,000 after buying an additional 1,310 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Akero Therapeutics by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock worth $412,000 after buying an additional 1,446 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.